IN8bio, Inc. (INAB) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by IN8bio, Inc. on June 2, 2025. The company is a Delaware corporation with principal executive offices in New York, New York, and its common stock trades on The Nasdaq Stock Market LLC under the symbol "INAB". The report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than periodic financial performance.
Material Changes and Events
Under Item 8.01 (Other Events), the company announced the presentation of Phase 1 clinical data for its investigational therapy, INB-200, in patients with newly diagnosed glioblastoma multiforme. The data, presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrated prolonged progression-free survival.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the context of the clinical trial results. The primary disclosure is the clinical milestone regarding INB-200.
Investor Verification Checklist
- Verify the full details of the Phase 1 data for INB-200 in the attached press release (Exhibit 99.1).
- Confirm the specific metrics for "prolonged progression-free survival" presented at the 2025 ASCO Annual Meeting.
- Review the company's most recent 10-Q or 10-K for current financial position, as this 8-K does not include financial statements.
- Monitor subsequent regulatory filings for updates on the development timeline of INB-200 following the ASCO presentation.